This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Excipients are inactive substances formulated with the active pharmaceutical ingredient (API) of a medication. Many excipients, like lactose, starch, and microcrystalline cellulose, contribute to the property, stability, safety, and many other aspects of drug manufacturing and have been widely used in the pharmaceutical industry [1]. Different kinds of excipients are frequently used together to achieve multiple properties for a medication; meanwhile, the ones that can improve the quality of pharmaceutical preparations or the production efficiency have attracted more and more attention [1, 2]. For instance, there have been several types of lactose excipient [3, 4], which have typical values of fluidity, viscosity, compressibility, particle size and particle size distribution, enteric disintegration performance, and so on. These values have great influence on the physical and chemical properties of pharmaceutical preparations, such as disintegration and dissolution and bioequivalence in vivo and in vitro. In practice, solid dosage forms require different types of excipients to be added to the API in order to obtain the desired physicochemical properties, such as flowability, compressibility, disintegration, solubility, and stability [4–8], for the medication. The excipients are mixed and granulated with the APIs using different equipment to ensure their mixing uniformity. The typical mixing and granulation techniques in the pharmaceutical industry include direct mixing, dry and wet granulation, spray drying, and freeze drying [9].
Agglomeration is the technique that binds small particles to create large aggregates. It is also presented as granulation in a macro sense, where pharmaceutical ingredients are frequently granulated with some excipients to create visible round particles for production of tablets and capsules [5, 6]. Through agglomeration/granulation technology, the APIs and excipients can be evenly mixed with a suitable particle size distribution and provide good material uniformity, fluidity, and compressibility for the subsequent preparation process, such as the tableting process [7]. A good agglomeration/granulation also contributes to the stability in transportation and storage, provides desired disintegration and dissolution, and ensures that the drug has the expected dissolution curve and AUC (area under the curve) in vivo, ensuring good absorption of the drug for a better therapeutic effect.
At present, typical agglomeration/granulation includes the formation of solid bridges, adhesion, sintering, chemical reaction, crystallization, and colloidal particle deposition [8, 9], among which dry granulation and wet granulation are the two main methods in practice [2, 10]. The dry granulation methods generally bind the fine particles by compression force, for those materials with good compressibility, namely, high molecular interactions. The wet granulation methods use a solvent (i.e., water), solution, or suspension as the binder to provide bridging forces required for the fine powders to form large particles. In this work, a fluidized bed agglomeration process was used to produce the agglomerated lactose. A suspension of lactose solution is sprayed onto the fluidized lactose particles, forming liquid bridges among the large and small lactose particles to form agglomerated lactose. The effects of agglomeration parameters, including solution concentration and temperature, atomizing pressure, peristalsis speed, and material temperature, were investigated for the agglomeration.
2. Materials and Methods
2.1. Preparation of Lactose Suspension
The pharmaceutical-grade α-lactose monohydrate (>99.9%) was purchased from Jiangsu Dawning Pharmaceutical Co., Ltd., China. Four groups of lactose solution were prepared with lactose concentrations of 5%, 15%, 25%, and 40% (
2.2. Agglomeration
The schematic diagram of the fluidized bed granulator and the agglomeration parameters is shown in Figure 1. In a typical agglomeration, 120 g milled lactose of 120 mesh and 100 g fine-milled lactose of 300 mesh were mixed and added into a fluidized bed granulator (Shenzhen Xinyite Technology Co., Ltd, China). The fluidized bed granulator was preheated for 30 minutes. 150 mL lactose suspension was gradually sprayed onto the fluidized lactose mixture in the granulator at a controlled spraying speed. 5 min of the subdry process was performed to ensure a stable temperature of the materials in the fluidized bed. An additional volume of 150 mL of lactose suspension was sprayed subsequently in order to investigate the effect of the binder. The agglomeration stopped after 600 mL lactose suspension was sprayed in total. The concentration, temperature, peristaltic speed, and atomizing pressure were investigated for the lactose agglomeration.
[figure omitted; refer to PDF]
In the agglomeration process, wet particles form liquid bridges when they coalesce. In the subsequent drying step, the solid bridges that hold the particles together form large particles from the liquid bridges. When the solution has a lactose concentration of 25%, the agglomeration rate constant
[figure omitted; refer to PDF]
Generally, small particles show poor flowability but good compressibility [13]. The result, however, shows that both the tablet hardness and the particle size of the agglomerated lactose increase at the same time (Figure 4) for the following possible reason. At a spray pressure of 20 MPa, atomized droplets were smaller than the size of lactose particles, where the agglomerated lactose particles were loose and were composed of fine-milled lactose linked through solid bridges formed after drying. The aggregation of fine particles was confirmed by SEM (Figure 5). The SEM shows that the surface of particles is porous and the structure is fluffy. When the particle size increases, more fine particles are aggregated resulting in increases in the compressibility (due to the number of fine particles) and the flowability (due to the size of the aggregates). The particles would have good flowability and good compressibility when the size is over 140 μm [14]. Besides, the temperature of the solution, the temperature of the material in the fluidized bed chamber and the spraying speed of lactose suspension play important roles in the agglomeration process, improving the granulation speed and efficiency. High temperatures and low spraying speeds of lactose suspension induce fast drying rates of the fluidized lactose, affecting the binding and formation of solid bridges among the fine lactose particles.
[figure omitted; refer to PDF]
[figures omitted; refer to PDF]
The DSC curve (Figure 6) shows that the agglomerated lactose is lactose monohydrate, where the dehydration peak is shown at 145°C. β-Lactose peak is shown alongside α-lactose peak, indicating that the process transfers α-lactose to β-lactose [15, 16]. According to the XRD spectrum (Figure 7), α-lactose peaks are observed at 2θ of 12.5°, 19.1°, 19.6°, and 19.9°. β-Lactose peaks are at 2θ of 10.5° and 20.8°, indicating that a small amount of β-lactose was produced [17, 18]. The FTIR spectra confirmed that the materials are lactose monohydrate [19] with a peak of -OH of water at 3600 cm-1 (Figure 8).
[figure omitted; refer to PDF][figure omitted; refer to PDF][figure omitted; refer to PDF]4. Conclusions
This work used a fluidized bed agglomeration process to produce the agglomerated lactose with good compressibility. In the fluidized bed agglomeration, large lactose crystals were used as the core materials, fine-milled lactose particles were bound to the surface of large lactose cores, and lactose solution was used as the binder. The fine-milled lactose of 300 mesh contributed to the compressibility of the agglomerated lactose. Good harness of the tablets around 75-88 N was achieved when 0.25 g agglomerated lactose was compressed with a diameter of 8 mm on a single-punch tablet press under a compression pressure of 10 MPa. The particle size and bulk density can be controlled. Instrumental analysis indicated the production of β-lactose.
Acknowledgments
This work was supported by the 131 Talent Engineering Fund (2020-32), Scientific Research Project of Hunan Provincial Department of Education (20C1156), Scientific Research Project of Hunan Provincial Health Commission (202115011227), and Clinical Pharmacy Project of Medical Research Fund of Hunan Medical Association (HMA202001008).
[1] J. B. M. Fernandes, M. T. Celestino, M. I. B. Tavares, Z. M. F. Freitas, E. P. D. Santos, E. Ricci Júnior, M. Monteiro, "The development and characterization of propranolol tablets using tapioca starch as excipient," Anais da Academia Brasileira de Ciências, vol. 91 no. 1, article e20180094,DOI: 10.1590/0001-3765201920180094, 2019.
[2] N. Garg, P. Pandey, D. Kaushik, H. Dureja, "Development of novel multifunction directly compressible co-processed excipient by melt granulation technique," International Journal of Pharmaceutical Investigation, vol. 5 no. 4, pp. 266-274, DOI: 10.4103/2230-973X.167692, 2015.
[3] S. Lute, R. Dhenge, A. Salman, "Twin screw granulation: effects of properties of primary powders," Pharmaceutics, vol. 10 no. 2,DOI: 10.3390/pharmaceutics10020068, 2018.
[4] S. Tan, A. Ebrahimi, T. Langrish, "Template-directed flower-like lactose with micro-meso-macroporous structure," Materials & Design, vol. 117, pp. 178-184, DOI: 10.1016/j.matdes.2016.12.077, 2017.
[5] T. Ito, K. Okada, K. H. Leong, D. Hirai, Y. Hayashi, S. Kumada, A. Kosugi, Y. Onuki, "A time-domain nmr study of the state of water in wet granules with different fillers and its contribution to the wet granulation process and to the characteristics of granules," Chemical and Pharmaceutical Bulletin, vol. 67 no. 3, pp. 271-276, DOI: 10.1248/cpb.c18-00888, 2019.
[6] N. Hirai, T. Takatani-Nakase, K. Takahashi, "Application of near-infrared spectrometry to evaluate the mechanism of wet granulation using a high-speed mixer with porous calcium silicate and sugar alcohols," Chemical and Pharmaceutical Bulletin, vol. 66 no. 11, pp. 1027-1034, DOI: 10.1248/cpb.c18-00474, 2018.
[7] S. Shanmugam, "Granulation techniques and technologies: recent progresses," BioImpacts, vol. 5 no. 1, pp. 55-63, DOI: 10.15171/bi.2015.04, 2015.
[8] L. Cai, L. Farber, D. Zhang, F. Li, J. Farabaugh, "A new methodology for high drug loading wet granulation formulation development," International Journal of Pharmaceutics, vol. 441 no. 1-2, pp. 790-800, DOI: 10.1016/j.ijpharm.2012.09.052, 2013.
[9] S. M. Iveson, J. D. Litster, K. Hapgood, B. J. Ennis, "Nucleation, growth and breakage phenomena in agitated wet granulation processes: a review," Powder Technology, vol. 117 no. 1-2,DOI: 10.1016/S0032-5910(01)00313-8, 2001.
[10] O. A. Adeleye, M. N. Femi-Oyewo, M. A. Odeniyi, "The effect of processing variables on the mechanical and release properties of tramadol matrix tablets incorporating Cissus populnea gum as controlled release excipient," Polymers in Medicine, vol. 44 no. 4, pp. 209-220, 2014.
[11] S. A. L. de Koster, K. Pitt, J. D. Litster, R. M. Smith, "High-shear granulation: an investigation into the granule consolidation and layering mechanism," Powder Technology, vol. 355, pp. 514-525, DOI: 10.1016/j.powtec.2019.07.076, 2019.
[12] M. Fujiwara, M. Dohi, T. Otsuka, K. Yamashita, K. Sako, "Influence of binder droplet dimension on granulation rate during fluidized bed granulation," Chemical and Pharmaceutical Bulletin, vol. 61 no. 3, pp. 320-325, DOI: 10.1248/cpb.c12-00969, 2013.
[13] Y. Kudo, M. Yasuda, S. Matsusaka, "Effect of particle size distribution on flowability of granulated lactose," Advanced Powder Technology, vol. 31 no. 1, pp. 121-127, DOI: 10.1016/j.apt.2019.10.004, 2020.
[14] Y. Özalp, M. M. Onayo, N. Jiwa, "Evaluation of lactose-based direct tableting agents' compressibility behavior using a Compaction Simulator," Turkish Journal of Pharmaceutical Sciences, vol. 17 no. 4, pp. 367-371, DOI: 10.4274/tjps.galenos.2019.94840, 2020.
[15] S. Tan, A. Ebrahimi, T. Langrish, "Preparation of core-shell microspheres of lactose with flower-like morphology and tailored porosity," Powder Technology, vol. 325, pp. 309-315, DOI: 10.1016/j.powtec.2017.11.028, 2018.
[16] S. Tan, A. Ebrahimi, X. Liu, T. Langrish, "Hollow flower-like lactose particles as potential drug carriers: effect of particle size and feed concentration," Powder Technology, vol. 320,DOI: 10.1016/j.powtec.2017.07.033, 2017.
[17] A. S. Barham, B. K. Hodnett, "In situ X-ray diffraction study of the crystallization of spray-dried lactose," Crystal Growth & Design, vol. 5 no. 5, pp. 1965-1970, DOI: 10.1021/cg050237c, 2005.
[18] S. Tan, T. Jiang, A. Ebrahimi, T. Langrish, "Effect of spray-drying temperature on the formation of flower-like lactose for griseofulvin loading," European Journal of Pharmaceutical Sciences, vol. 111, pp. 534-539, DOI: 10.1016/j.ejps.2017.10.040, 2018.
[19] S. Tan, A. Ebrahimi, X. Liu, T. Langrish, "Role of templating agents in the spray drying and postcrystallization of lactose for the production of highly porous powders," Drying Technology, vol. 36 no. 15, pp. 1882-1891, DOI: 10.1080/07373937.2018.1445096, 2018.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2021 Bo Wang et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0/
Abstract
In this work, a fluidized bed agglomeration process was used to produce agglomerated lactose with good compressibility. In the fluidized bed agglomeration, large lactose crystals were used as the core materials, fine-milled lactose particles were bound to the surface of large lactose cores, and lactose solution was used as the binder. A suspension of lactose solution is sprayed onto the fluidized lactose particles, forming liquid bridges among the large and small lactose particles to form agglomerated lactose. Good hardness of 75-88 N was achieved for the agglomerated lactose. The particle size and bulk density can be controlled. The effects of agglomeration parameters, including solution concentration and temperature, atomizing pressure, peristalsis speed, and material temperature, were investigated for the agglomeration result and the characteristics of the agglomerated lactose. The result also shows that high solution temperature and high solution concentration can improve fluidized bed agglomeration efficiency.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Wang, Junyan 3
1 Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410000, China
2 Drug Clinical Trial Institution Department, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan 410000, China
3 Faculty of Engineering, Monash University, Melbourne 3800, Australia





